Skip to Content
  • HAT Inhibitors: Interpret With Care

    There are quite a few histone deacetylase inhibitors out there, from research tools to FDA-approved drugs. Those inhibit the enzymes that remove the acetyl epig… Read More
  • An Odd Paper?

    Nanoparticles came up around here the other day, and now a reader sends along a new paper in the field that’s. . .a bit odd. Maybe more than a bit. ItR… Read More
  • Small Proteins: Into the Gap

    We medicinal chemists are used to thinking about small molecule drugs – it’s what we do. And we’re also comfortable with having a category in… Read More
  • The Old School

    I enjoyed this piece on “The Changing Culture of Chemistry”. The author, Bruce Gibb of Tulane, has in mind the changes that are apparent when you re… Read More
  • More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a… Read More
  • When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the… Read More
  • Silicon Stays in the Shadows

    I like this review, but I’ve seen it before. Well, not this exact manuscript, but every few years it seems there’s another one with a similar title… Read More
Page 2 of 1512345...10...Last »